Yes, you can start Zepbound (tirzepatide) while taking Eliquis (apixaban)
There are no known direct drug interactions between tirzepatide and apixaban, and they can be safely co-administered. The FDA labeling for Eliquis does not list tirzepatide as a contraindicated or interacting medication 1, and current guidelines support the use of tirzepatide in patients requiring anticoagulation 2.
Key Considerations
No Pharmacokinetic Interaction
- Eliquis is metabolized through P-glycoprotein (P-gp) and CYP3A4 pathways 1
- Tirzepatide, as a GLP-1/GIP receptor agonist, does not significantly affect these metabolic pathways
- The only drugs requiring Eliquis dose adjustment are combined P-gp and strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir) 1—tirzepatide is not among these
Complementary Therapeutic Benefits
According to 2025 BMJ guidelines, tirzepatide can be combined with other cardiovascular medications and should not replace therapies effective for cardiovascular and kidney complications 2. This explicitly supports concurrent use with anticoagulants when indicated.
Important Caveats
Bleeding Risk Monitoring
While there's no direct interaction, maintain standard bleeding precautions for any patient on anticoagulation:
- Monitor for signs of bleeding (bruising, GI bleeding, hematuria)
- The most common adverse events with tirzepatide are gastrointestinal (nausea, vomiting, diarrhea) 2, 3, 4
- GI side effects could theoretically complicate detection of GI bleeding, so counsel patients to report any concerning symptoms
Warfarin Exception
If the patient were on warfarin instead of Eliquis, closer INR monitoring would be warranted. A 2025 case report documented that tirzepatide may indirectly affect warfarin's pharmacokinetics through delayed gastric emptying, requiring warfarin dose adjustments 5. However, this concern does not apply to Eliquis, which has a predictable pharmacokinetic profile that doesn't require routine monitoring 1.
Cardiovascular Considerations
- Tirzepatide provides substantial weight loss benefits (mean 8.63 kg reduction) 2
- For patients with obesity at higher cardiovascular risk, tirzepatide should generally be added to—not replace—medications with proven cardiovascular benefits 2
- One case report noted marked tachycardia in a POTS patient on tirzepatide 6, but this is not a contraindication for general use
Practical Implementation
Start tirzepatide at the standard initial dose (typically 2.5 mg weekly, titrating as tolerated) while continuing Eliquis at its prescribed dose without modification 2, 4. No special monitoring beyond standard anticoagulation follow-up is required.